Pyxis Oncology, Inc. (PYXS): Cash & Equivalents
$15.42M
As of 2025-12-31
$18.86M
As of 2026-06-30
-55.9%
3-year compound annual growth
+13.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.42M | -20.8% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $19.47M | +101.5% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $9.66M | -94.6% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $179.29M | -34.7% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $274.74M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | $8.08M | n/a | 2022-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $15.42M | -20.8% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.01M | -50.4% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $45.09M | +48.7% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $7.49M | +192.2% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $207.64M | +110.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $44.06M | +171.1% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $2.13M | +53.1% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $35.26M | +182.6% |
| uniQure N.V. (QURE) | 2025-12-31 | $80.24M | -49.5% |
Compare PYXS, ABUS, IRD, PTN side by side · Screen every company in Pharmaceutical Preparations ↗